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In contrast to most other cancer therapies, early 
research with oncolytic viruses (OV) tended to use 
direct or intratumoural routes of administration, initially 
motivated by concerns that the major limitation of 
intravenous delivery would be immune attack against 
the viruses, whether by complement, cytokine or most 
critically neutralising antibodies. Even in the absence of 
preformed circulating neutralising antibodies, antiviral 
immunity develops rapidly over the course of multiple 
viral administrations [1]. Preclinically ex vivo cell 
preparations have been used to load virus onto or into 
assorted cells, including white blood cells (often called 
‘hitchhiking’), but such manoeuvres would be difficult to 
implement clinically.
Given these perceived limitations, many have 
chosen direct administration to maximise intratumoural 
delivery: H101 (an oncolytic adenovirus with selectivity 
against p53-defective tumour cells) is approved in China 
and is given intratumourally for head and neck cancers. 
Several viruses have been administered into the tumour 
bed perioperatively for glioma. Measles has been 
administered intraperitoneally in ovarian cancer. One of 
the field-leading products is T-Vec (aka OncoVex), an 
engineered herpes virus. Its recent acquisition by Amgen 
was a fillip for those in the OV field, and was based on 
promising phase II data in melanoma where the virus was 
injected intratumourally into all accessible lesions [2]; a 
phase III study has closed to recruitment and results are 
keenly awaited. However these direct delivery routes are 
unpleasant for patients, unpopular with clinicians and 
unachievable for many deep-seated tumours [3]. 
We previously recovered replication-competent 
reovirus from tumour following intravenous infusion in 
three patients with head and neck cancer, [4]  a finding 
recently replicated by Breitbach and colleagues using 
JX-594, an engineered vaccinia derivative [5]. Following 
intravenous injection JX594 was detected in whole blood 
by quantitative polymerase chain reaction (qPCR) for 
at least four hours after infusion. Patients underwent 
tumour biopsies 8-10 days after viral administration, 
and these biopsies were examined by PCR and by 
immunohistochemistry (IHC) for native viral protein and 
expression of the engineered marker gene. Amongst the 
eight subjects treated in the higher dose cohorts, all eight 
had at least one positive viral marker; four were positive 
across all three assays.
These vital observations that two different viruses, 
administered intravenously, reach tumour tissues strongly 
support the further development of OV for systemic use 
in metastatic disease. However, neither of these studies 
completely addressed the issue of how a systemically 
administered virus might successfully run the gauntlet of 
anti-viral immunity. 
Reovirus is an endemic human pathogen and, 
therefore, neutralising anti-reovirus antibodies (NARA) 
are extremely prevalent in the population. In contrast 
vaccinia is not present in the environment and routine 
vaccination against smallpox ended in North America 
in the mid-1970s. In fact only one of the subjects treated 
with high-dose JX-594, in whom virus was detectable in 
the tumour, had pre-existing neutralising anti-vaccinia 
antibodies. In addition it is highly likely that successful 
virotherapy will require several doses of OV, which 
will induce high titres of neutralising antibodies in most 
patients. 
Against this background, we have recently 
confirmed successful intravenous delivery of reovirus 
in a population of pre-immune cancer patients [6]. In a 
phase Ib study we administered intravenous reovirus to 
10 patients prior to surgical resection of colorectal hepatic 
metastases. Patients received up to 5 daily infusions of 
reovirus, 6-28 days before surgery. Cell suspensions 
prepared from a number of tumours yielded replicating 
reovirus, but adjacent normal liver tissue did not. IHC 
confirmed these results and provided evidence of selective 
reovirus replication within tumours. 
Importantly, all patients in the study had detectable 
neutralising antibodies before treatment and NARA titres 
peaked in all patients by the time of surgery. Accordingly, 
although reovirus was detected by PCR in the plasma 
of patients shortly after infusion, we were unable to 
recover replicating virus from plasma. This finding is 
compatible with NARA functionally neutralising the virus 
in the circulation. However we recovered replication-
competent virus from the peripheral blood mononuclear 
cell, granulocyte and platelet fractions of the patients’ 
blood. These data indicate that virus hitchhikes on 
these circulating blood cells, circumventing the anti-
viral immune response to access tumour.  Hitchhiking 
virus onto ex vivo-cultured carrier cells is an area that 
we and others have explored preclinically [7,8], but had 
never been addressed in patients before. Remarkably our 
results demonstrate that this phenomenon occurs in vivo 
following intravenous administration of neat virus. Further 
work to characterise and enhance the mechanism of viral 
carriage is underway, and will be critical to optimising 
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systemic virotherapy. 
It is an exciting time to be involved in OV research. 
Preclinical developments continue to inform the clinical 
approach and provide novel targeted or armed agents for 
therapeutic testing [9]. Clinical studies have moved from 
addressing initial concerns about the safety of patients (and 
their attendants) to examining viral efficacy; thankfully 
there are reassuring data to address both questions. 
Understandable concerns about the fate of intravenously 
administered OV led to an initial preponderance of 
clinical trials examining direct routes of administration, 
but the three studies outlined above demonstrate that the 
intravenous delivery of OV is achievable, and anti-viral 
immunity is surmountable. We expect this will inform 
the next tranche of trials, as OV hopefully move from 
experimental therapies to mainstream cancer treatments. 
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